Hypopharyngeal cancer, a type of head and neck cancer, develops in hypopharynx. Pharynx is a hollow tube about five inches long, and the bottom part of the pharynx called hypopharynx. Most of the hypopharyngeal malignancy occurs in squamous cells. Some of the major risk factors associated with the disease are smoking, heavy drinking, tobacco consumption, Plummer-Vinson syndrome, and intake of nutrient deficit diet. The signs and symptoms of the disease are ear pain, voice change, sore throat, difficulty in swallowing, and lump in the neck. Biotech Pharmaceutical Co. Ltd. (BPL) is in the process of developing nimotuzumab as an epidermal growth factor receptor antagonist for the treatment of hypopharyngeal cancer. Novartis AG, and the Stanford University are also involved in development of drugs for hypopharyngeal cancer.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.